BioLineRx to Present GLIX1 Ovarian Cancer Data at ESMO 2026
TEL AVIV, Israel & OSLO, Norway, July 20, 2026 BioLineRx Ltd. and Hemispherian AS have announced that new preclinical...
glioblastoma
Advertisement
IN8bio Publishes Positive Phase 1 GBM Data
NEW YORK, July 9, 2026 IN8bio announced the publication of peer-reviewed Phase 1 clinical trial results for its investigational...
Northwest Biotherapeutics to Present DCVax-L Survival Analysis at BNOS 2026
BETHESDA, Md., July 2, 2026 Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will deliver a...
CraniUS Secures NIH Grant for Glioblastoma Therapy
BALTIMORE, June 29, 2026 CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of Health...
Siren Biotechnology Secures $8M CIRM Grant for SRN-101 Trial
SAN FRANCISCO, Calif., June 26, 2026 Siren Biotechnology has been awarded an $8 million non-dilutive CLIN2 grant from the...
Advertisements
Knoa Pharma and GCAR Expand Glioblastoma Trial Efforts
STAMFORD, Conn., June 24, 2026 Knoa Pharma LLC and the Global Coalition for Adaptive Research (GCAR) announced a significant...
Novocure Reports Phase 3 TRIDENT Trial Results
BAAR, Switzerland | June 18, 2026 Novocure has announced topline results from its Phase 3 TRIDENT trial, which evaluated...
NeOnc Expands International Clinical Development of NEO212 for Glioblastoma
CALABASAS, Calif., June 16, 2026 NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH)...
Trogenix Doses First Patient in TGX-007 Glioblastoma Trial
Edinburgh, UK | May 28, 2026 Clinical-stage oncology company Trogenix announced the first patient has been dosed in the...
BioLineRx and Hemispherian Showcase GLIX1 Cancer Data at ASCO 2026
Tel Aviv, Israel and Oslo, Norway – May 22, 2026 BioLineRx Ltd. and Hemispherian AS announced new preclinical and...
Advertisement
